Navigation Links
More Than Half of Patients Treated for Benign Prostatic Hyperplasia Receive Boehringer Ingelheim's Flomax as First-Line Therapy
Date:4/7/2008

e effects such as retrograde ejaculation, decreased libido, and hypotension as well as patients' belief that symptoms will go away on their own are key reasons for the low drug-treatment rate.

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithm Insight Series provide the following:

-- Summary of U.S. medical practice based on interviews with leading

experts in the field.

-- Qualitative diagnosis/referral/treatment algorithm for the United

States.

-- Drug usage by lines of therapy (1st, 2nd, 3rd line).

-- Discussion of key freeform combinations by lines of therapy.

-- Product share (class and specific compound level) within each line of

therapy (1st, 2nd, 3rd line).

-- Progression of therapy from key 1st line products.

-- Pathway to key therapies from previous therapies.

-- Qualitative analysis of two-year forecast incorporating upcoming

launches, changes in reimbursement, etc.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

78
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
5. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
8. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
9. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
10. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
11. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013  Continuing its long history ... (MI), Beckman Coulter , Inc. announces the U.S. ... new Access AccuTnI+3 troponin I assay for use on ... have depended on Beckman Coulter,s troponin I ... assay has the proven performance to continue providing dependability ...
(Date:6/19/2013)... Today DuPont Executive Vice President James ... in the greatest challenge facing our time – ensuring ... Borel spoke at the International Food and Agribusiness ... need for students to contribute their time and talents ... reached in collaboration with others. , “Food is one ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 BioConvergence ... the speaking faculty at 2013’s BioLogistics Summit in ... conference, coordinated by Cold Chain IQ and IQPC, ... This “complexity” is, in part, attributed to current ... , “Implicit within these trends is an increase ...
(Date:6/19/2013)... (PRWEB) June 18, 2013 A new ... materials, costs and other trends will highlight technical sessions ... California this fall. In its 33rd year, the three-day ... an exhibition of key suppliers, approximately 100 technical presentations ... SPIE, the international society for optics and photonics , ...
Breaking Biology Technology:Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 3DuPont Leader Calls for New Generation of Food Visionaries to Fight Hunger 2BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3
... 2 GlaxoSmithKline plc (GSK),announced today that Fountain ... a cash tender offer to purchase all,outstanding shares ... SIRT ) (Sirtris), for $22.50 in cash without ... offer is being made pursuant to a,previously announced ...
... P3(TM) Technology Raising the Bar in Motion Preservation, ... Technology,Inc., a leader in innovative medical devices, announced ... cervical total disc,replacement (TDR), NuNec Cervical Arthroplasty Device. ... Zou and Wenwen Wu in Beijing China, on,patients ...
... to $11.7 million, -- Quarterly Net Income Increases ... NEW YORK and HAIKOU, Hainan, China, May ... (OTC Bulletin Board: CPHI),which develops, manufactures, and markets ... its financial results,for the first quarter of 2008., ...
Cached Biology Technology:GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals 2GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals 3Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device 2China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 2China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 3China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 4China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 5China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 6China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 7China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 8China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 9
(Date:6/19/2013)... The Microbial Diversity Course at the Marine Biological ... a Milestones in Microbiology site by the American ... in Microbiology program recognizes institutions and the scientists ... toward advancing the science of microbiology. A ... site is scheduled for Saturday, June 22, 2013, ...
(Date:6/19/2013)... June 19, 2013 AT&T * ... upcoming launch of the ultimate workhorse among ruggedized ... As one of the most ruggedized phones equipped ... Terrain embodies toughened versatility and business-ready features.  Its ... keep workforces moving forward, while also keeping up ...
(Date:6/19/2013)... A new variety of canary seeds bred specifically for ... be ideal for people with celiac disease (CD), scientists ... Journal of Agricultural and Food Chemistry . , ... least 3 million people in the United States alone ... eating wheat, barley, rye and other grains that contain ...
Breaking Biology News(10 mins):Microbial diversity course designated as a 'Milestones in Microbiology' site 2AT&T and NEC Introduce Ultra-Rugged Smartphone Designed for Hard Work, Real Life 2AT&T and NEC Introduce Ultra-Rugged Smartphone Designed for Hard Work, Real Life 3AT&T and NEC Introduce Ultra-Rugged Smartphone Designed for Hard Work, Real Life 4AT&T and NEC Introduce Ultra-Rugged Smartphone Designed for Hard Work, Real Life 5
... across Europe are embarking on new research to develop a ... million EU citizens and there is no cure," says Dr ... partner in the Food Allergy Specific Therapy (FAST) research project. ... foods to which they are allergic. The threat of severe ...
... Biology are pleased to announce that Dr Audrey ... of this year,s JEB Outstanding Paper Prize. The award ... Journal of Experimental Biology at http://jeb.biologists.org ., ... young scientist to an exceptional research paper. Dussutour was ...
... environmental threat has been detected in North American ... Along with scientists from several Canadian government ... by declining levels of calcium in many temperate, ... Queen,s PhD candidate Adam Jeziorski, lead author of ...
Cached Biology News:Scientists developing food allergy treatment 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 3Queen's University biologists find new environmental threat in North American lakes 2
... Epithelial and endothelial cells-directed ... a RGD peptide-conjugated polyethylenimine which ... integrin-expressing epithelial and endothelial cells. ... in cell-cell and cell-matrix adhesion ...
... WinMelt software is used to ... any DNA sequence up to ... optimizing placement of primers and ... by denaturing gradient gel electrophoresis ...
Request Info...
... Accurate To score SNPs, ... sequencing, the gold standard in DNA analysis. ... The polymorphic locus can be confirmed by ... DNA sequencing also provides sequence context information, ...
Biology Products: